Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors found in the gastrointestinal tract of dogs and are characterized by specific cellular markers. These tumors ...

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

By staying abreast of signs and risk factors, such as persistent indigestion, unexplained weight loss, or discomfort in the ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...